Novartis unveils vision for Sandoz-free future based on key tech and US market

As with any big pharma company, Swiss giant Novartis (NOVN: VX) periodically holds events to inform shareholders and other interested parties on its updated strategy and optimism for future drug sales.

Sometimes these events do yield new insights into the company’s plans and on other occasions they can appear to be prosaic functions in the corporate calendar.

Change and controversy